We design novel proximity-inducing compounds (PICs™), to treat diseases with high unmet medical need. Our patent-filed approach uses active machine learning to predict biomolecular interactions and generate new chemical entities. The wholly-owned pipeline is focused on degrader development in oncology and CNS disorders, while we are open to partnerships across all indication areas. Watch the video to learn more.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.